Ftse Mib
37.977,59
0,18%
DAX
22.513,42
-0,43%
S&P 500
6.114,63
-0,01%
NASDAQ
20.026,77
0,41%
Bitcoin
97.063,96
-0,54%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lexeo Therapeutics Inc (LXEO) Lexeo Therapeutics Inc (LXEO) Notizie

Lexeo Therapeutics Inc

LXEO
4,55
0,33 (7,82%)
15 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/2/202515:35EDGAR2Form SCHEDULE 13G/A - Statement of Beneficial Ownership by..
04/2/202521:45EDGAR2Form SCHEDULE 13G - Statement of Beneficial Ownership by..
22/1/202522:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/1/202513:35EDGAR2Form 8-K - Current report
10/1/202522:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202522:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202522:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202522:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202522:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/1/202513:30GLOBELexeo Therapeutics to Present at the 43rd Annual J.P. Morgan..
27/12/202420:59EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/12/202413:01EDGAR2Form 8-K - Current report
19/12/202413:00GLOBELexeo Therapeutics Appoints Kyle Rasbach as Chief Financial..
13/12/202414:19EDGAR2Form S-3 - Registration statement under Securities Act of..
12/12/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/12/202423:18EDGAR2Form 144 - Report of proposed sale of securities
02/12/202423:04EDGAR2Form POS AM - Post-Effective amendments for registration..
13/11/202423:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202413:35EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13/11/202413:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202413:32EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13/11/202413:31EDGAR2Form 8-K - Current report
13/11/202413:30GLOBELexeo Therapeutics Provides Update on Cardiac Portfolio and..
30/10/202411:17EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
30/10/202411:15EDGAR2Form 8-K - Current report
30/10/202411:14GLOBELexeo Therapeutics Announces Positive Interim Data for..
22/10/202413:30GLOBELexeo Therapeutics to Present New Interim Data from Phase..
15/10/202419:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/10/202422:32EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
09/10/202422:30EDGAR2Form 8-K - Current report
11/9/202423:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/9/202422:39EDGAR2Form 144 - Report of proposed sale of securities
05/9/202413:30GLOBELexeo Therapeutics to Participate in Upcoming Investor..
14/8/202400:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/8/202413:11EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
12/8/202413:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/8/202413:01EDGAR2Form 8-K - Current report
12/8/202413:00GLOBELexeo Therapeutics Reports Second Quarter 2024 Financial..
15/7/202413:59EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/7/202413:55EDGAR2Form 8-K - Current report
15/7/202412:00GLOBELexeo Therapeutics Announces Positive Interim Phase 1/2..
12/7/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/7/202414:00GLOBELexeo Therapeutics Announces Investor Webcast to Report..
08/7/202413:04EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/7/202413:01EDGAR2Form 8-K - Current report
08/7/202413:00GLOBELexeo Therapeutics Appoints Tim Van Hauwermeiren to its..
14/6/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202423:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/5/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 4,56 Min: 4,26 Max: 4,575
Chiusura: 4,22

La tua Cronologia

NASDAQ
LXEO
Lexeo Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci